FindTrial
Sign In

Silodosin as birth control pill for males

Prospective double blind randomised study to evaluate the efficacy of silodosin 8 mg as on demand, reversible, male oral contraceptive

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/09/009872
Enrollment
100
Registered
2017-09-20
Start date
Unknown
Completion date
Unknown
Last updated
2024-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Silodosin 8 mg and Placebo: After obtaining written informed consent, sexually active males were included in the study. Those with sexual dysfunction, infertility, previous surgery, ano

Sponsors

TSS Hospital Sirsi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Sexually active males opting for contraception are included

Exclusion criteria

Exclusion criteria: Those with sexual dysfunction, infertility, previous surgery, anomalies / instrumentation of their GU tract are excluded

Design outcomes

Primary

MeasureTime frame
Number of un intended pregnanciesTimepoint: 6 months—

Secondary

MeasureTime frame
Adverse events related to silodosin intakeTimepoint: 6 months—

Countries

India

Contacts

Public ContactDr Gajanan Bhat

Department of Urology

gajubhatru@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 3, 2026